Highest-materiality recent filing
Ainos FY2025 revenue up 499%, gross margin 82.9%; AI Nose deployments scaling in semiconductor
Revenue up ~499% YoY; gross margin improved to 82.9% from a gross loss in 2024.
Ainos Q3 2025 results omit financials; focuses on AI Nose partnerships and patents
No net revenue or EPS disclosed in Q3 2025 press release; SG&A down 22% YoY, total opex down 8%.
Ainos Q2 2025 results highlight $2.1M AI Nose order and commercial momentum
Secured $2.1M three-year subscription order from ASEH for AI Nose in semiconductor manufacturing.
Ainos secures $2.1M order with ASE for AI Nose deployment in semiconductor manufacturing
Three-year subscription order valued at $2.1M from ASE Technology Holding, the world's largest semiconductor assembly and test provider.
Ainos regains Nasdaq compliance; sets 90-day AI Nose scale plan with 412% Q1 revenue jump
Nasdaq confirmed compliance on July 15, 2025; closing bid price >= $1.00 for 10 consecutive days.
Ainos forms strategic partnership with Kenmec to deploy AI Nose in smart factories
Legally binding strategic partnership announced June 24, 2025.
Revenue up 412% YoY to $106,207; gross profit of $87,974 vs prior-year gross loss of $6,025.
Ainos signs MOU with ASE to deploy AI Nose for semiconductor VOC detection
Ainos (AIMD) and Advanced Semiconductor Engineering (ASE) signed a legally binding MOU to integrate AI Nose into ASE's 46 fully automated factories.
Ainos reports FY2024 revenue $20,729, net loss $14.9M; AI Nose and VELDONA progress
Revenue fell 83% YoY to $20,729; cost of revenues $52,595; gross loss narrowed to $31,866.
Ainos partners with ugo to integrate AI Nose into robots for scent detection
Ainos (AIMD) and ugo, Japan's largest service robot firm, to develop first smell-enabled robot.
Ainos signs non-binding MOU with Taiwan Tanabe for VELDONA manufacturing and Taiwan market
Non-binding MOU with Taiwan Tanabe Seiyaku (Mitsubishi Tanabe subsidiary) for exclusive marketing, manufacturing, and marketing authorization of VELDONA in Taiwan.
Issued 5.5M shares to TCNT for exclusive, irrevocable, perpetual license of gas-sensor and medical-device patents.
Ainos receives Nasdaq deficiency notice for bid price below $1; 180 days to cure
Nasdaq notified Ainos that its common stock bid price closed below $1.00 for 30 consecutive business days.
Clinical trials for AI Nose-powered Ainos Flora achieved 75 meaningful case results, validating AI algorithm model.
Ainos Q1 revenue down 58% YoY to $20.7K; net loss widens to $3.3M; secures $9M convertible note
Revenue of $20,729 in Q1 2024, down 58% from $49,164 in Q1 2023, due to pivot from COVID-19 test kits.
Ainos issues $9M convertible note to ASE Test, with warrant for 500k shares
$9,000,000 convertible note, 6% compound interest, matures May 3, 2027.
As of August 9, 2024, Lawrence K. Lin transitioned from his role as the Company’s Executive Vice President of Operations, effective August 9, 2024.
On March 15, 2024, the Board of Directors appointed Christopher Hsin-Liang Lee as the Chief Financial Officer of Ainos, Inc. (the “Company”).
On March 13, 2024, Meng-Lin Sung, the Chief Financial Officer of Ainos, Inc. (the “Company”), resigned from her positions with the Company, effective as of such date.
Max materiality 0.75 · Median 0.57 · Most common event other_material